Pancreatic Cancer Research

ResearcherJesse Brown VA Medical CenterActive in the last 2 years

David J. Bentrem

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-2506-6187; OpenAlex author ID A5043187990, A5110864209, A5112809347, A5135551715. Sources: OpenAlex.

Their work

Papers
36 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2011: 5 papers · 2012: 3 papers · 2013: none · 2014: 6 papers · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 7 papers

Papers 36

  1. Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.70296↗
  2. Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes… Co-author DOI 10.1002/jso.70387↗
  3. Quantitative KRAS mutational burden by next-generation sequencing predicts outcomes in localized pancreatic cancer Co-author DOI 10.1016/j.surg.2026.110303↗
  4. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000006562↗
  5. High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-26-0609↗
  6. KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20447-0↗
  7. ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer Co-author DOI 10.1245/s10434-026-20549-9↗
  8. Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006209↗
  9. Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. Co-author DOI 10.1158/1535-7163.mct-23-0833↗
  10. Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer. Co-author DOI 10.3390/cells12111490↗
  11. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. First author DOI 10.1002/jso.26369↗
  12. Advances in Pancreatic Cancer 2021: Introduction. Co-author DOI 10.1002/jso.26437↗
  13. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Co-author DOI 10.3390/cancers13030440↗
  14. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection. Co-author DOI 10.1245/s10434-019-08023-1↗
  15. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Co-author DOI 10.1016/j.surg.2017.09.022↗
  16. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Co-author DOI 10.1371/journal.pone.0202272↗
  17. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2016.11.039↗
  18. A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer. Co-author DOI 10.1007/s11605-015-2957-2↗
  19. Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-15-0285↗
  20. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3398↗
  21. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Co-author DOI 10.1038/srep09489↗
  22. Quantitative functional MRI in a clinical orthotopic model of pancreatic cancer in immunocompetent Lewis rats. Co-author PMID 26550449↗
  23. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  24. CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Co-author DOI 10.1097/coc.0b013e318280d5f0↗
  25. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Last author DOI 10.1097/sla.0000000000000378↗
  26. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  27. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Co-author DOI 10.1158/1535-7163.mct-13-0925↗
  28. National assessment of margin status as a quality indicator after pancreatic cancer surgery. Co-author DOI 10.1245/s10434-013-3338-2↗
  29. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. Last author DOI 10.1016/j.jss.2011.09.020↗
  30. Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. Co-author DOI 10.1074/jbc.m111.308940↗
  31. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Co-author DOI 10.1136/gutjnl-2011-300821↗
  32. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized panc… Co-author DOI 10.1016/j.ijrobp.2010.02.030↗
  33. Apigenin down-regulates the hypoxia response genes: HIF-1α, GLUT-1, and VEGF in human pancreatic cancer cells. Last author DOI 10.1016/j.jss.2010.10.041↗
  34. Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression. Co-author DOI 10.1038/onc.2010.485↗
  35. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. Co-author DOI 10.1074/jbc.m110.195628↗
  36. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Co-author DOI 10.1158/0008-5472.can-10-1855↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akhil Chawla · 8 shared papers, 2025–2026 · strength 1.95
  2. Dominic J. Vitello · 7 shared papers, 2021–2026 · strength 1.76
  3. M.C. Cox · 7 shared papers, 2025–2026 · strength 1.70
  4. Alex Horowitz · 5 shared papers, 2026 · strength 1.25
  5. Krishay Sridalla · 5 shared papers, 2026 · strength 1.25
  6. Dhavan Shah · 5 shared papers, 2024–2026 · strength 1.14
  7. Hidayatullah G. Munshi · 12 shared papers, 2011–2024 · strength 0.91
  8. Mario A. Shields · 6 shared papers, 2011–2024 · strength 0.49
  9. Marina Talamonti · 8 shared papers, 2012–2018 · strength 0.41
  10. Krishan Kumar · 4 shared papers, 2014–2023 · strength 0.36
  11. Thao D. Pham · 2 shared papers, 2021–2024 · strength 0.35
  12. Shishir Kumar Maithel · 3 shared papers, 2014–2026 · strength 0.31
  13. Ishan Roy · 1 shared paper, 2026 · strength 0.29
  14. Flavio G. Rocha · 1 shared paper, 2021 · strength 0.28
  15. George Molina · 1 shared paper, 2026 · strength 0.25
  16. Judy Caroline Boughey · 1 shared paper, 2026 · strength 0.25
  17. Dhruv J. Patel · 1 shared paper, 2026 · strength 0.25
  18. Brett Logan Ecker · 1 shared paper, 2026 · strength 0.25
  19. John P. Hayes · 1 shared paper, 2026 · strength 0.25
  20. Marshall S. Baker · 4 shared papers, 2014–2018 · strength 0.25
  21. Richard A. Prinz · 4 shared papers, 2014–2018 · strength 0.25
  22. Jeffrey H. Becker · 1 shared paper, 2024 · strength 0.22
  23. Ryan P. Merkow · 3 shared papers, 2014–2020 · strength 0.22
  24. Rosa F. Hwang · 1 shared paper, 2023 · strength 0.20
  25. Surabhi Y. Dangi-Garimella · 6 shared papers, 2011–2012 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.